GB1583961A - Prostacyclin and derivatives thereof - Google Patents
Prostacyclin and derivatives thereof Download PDFInfo
- Publication number
- GB1583961A GB1583961A GB19384/76A GB1938476A GB1583961A GB 1583961 A GB1583961 A GB 1583961A GB 19384/76 A GB19384/76 A GB 19384/76A GB 1938476 A GB1938476 A GB 1938476A GB 1583961 A GB1583961 A GB 1583961A
- Authority
- GB
- United Kingdom
- Prior art keywords
- compound
- deoxy
- didehydro
- sodium
- prostaglandin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 229960001123 epoprostenol Drugs 0.000 title claims description 61
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 title claims description 60
- 150000001875 compounds Chemical class 0.000 claims abstract description 56
- 150000003180 prostaglandins Chemical class 0.000 claims abstract description 25
- 150000003839 salts Chemical class 0.000 claims abstract description 25
- -1 alkali metal alkoxide Chemical class 0.000 claims abstract description 15
- 229910052783 alkali metal Inorganic materials 0.000 claims abstract description 6
- 238000006704 dehydrohalogenation reaction Methods 0.000 claims abstract description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 42
- 238000000034 method Methods 0.000 claims description 38
- 239000000203 mixture Substances 0.000 claims description 27
- 239000001257 hydrogen Substances 0.000 claims description 18
- 229910052739 hydrogen Inorganic materials 0.000 claims description 18
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 17
- 238000009472 formulation Methods 0.000 claims description 17
- 159000000000 sodium salts Chemical class 0.000 claims description 17
- 239000000243 solution Substances 0.000 claims description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 15
- 230000002744 anti-aggregatory effect Effects 0.000 claims description 15
- 238000011534 incubation Methods 0.000 claims description 15
- 230000008569 process Effects 0.000 claims description 15
- 238000006243 chemical reaction Methods 0.000 claims description 14
- 210000001519 tissue Anatomy 0.000 claims description 14
- 210000001772 blood platelet Anatomy 0.000 claims description 13
- 210000001589 microsome Anatomy 0.000 claims description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical group CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 12
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 claims description 12
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 12
- 150000001768 cations Chemical class 0.000 claims description 12
- 239000011734 sodium Substances 0.000 claims description 12
- 241000124008 Mammalia Species 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 11
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 10
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 10
- 210000000709 aorta Anatomy 0.000 claims description 10
- 150000004702 methyl esters Chemical class 0.000 claims description 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 230000015572 biosynthetic process Effects 0.000 claims description 8
- 229910052708 sodium Inorganic materials 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 7
- SGUKUZOVHSFKPH-UHFFFAOYSA-N PGG2 Natural products C1C2OOC1C(C=CC(OO)CCCCC)C2CC=CCCCC(O)=O SGUKUZOVHSFKPH-UHFFFAOYSA-N 0.000 claims description 7
- 150000002148 esters Chemical group 0.000 claims description 7
- SGUKUZOVHSFKPH-YNNPMVKQSA-N prostaglandin G2 Chemical compound C1[C@@H]2OO[C@H]1[C@H](/C=C/[C@@H](OO)CCCCC)[C@H]2C\C=C/CCCC(O)=O SGUKUZOVHSFKPH-YNNPMVKQSA-N 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims description 7
- LMHIPJMTZHDKEW-XQYLJSSYSA-M Epoprostenol sodium Chemical compound [Na+].O1\C(=C/CCCC([O-])=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 LMHIPJMTZHDKEW-XQYLJSSYSA-M 0.000 claims description 6
- 239000007983 Tris buffer Substances 0.000 claims description 6
- QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical group C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 claims description 6
- 229940114079 arachidonic acid Drugs 0.000 claims description 6
- 235000021342 arachidonic acid Nutrition 0.000 claims description 6
- 239000002585 base Substances 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 6
- 230000007062 hydrolysis Effects 0.000 claims description 6
- 238000006460 hydrolysis reaction Methods 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 6
- 125000006239 protecting group Chemical group 0.000 claims description 6
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- DZUXGQBLFALXCR-UHFFFAOYSA-N (+)-(9alpha,11alpha,13E,15S)-9,11,15-trihydroxyprost-13-en-1-oic acid Natural products CCCCCC(O)C=CC1C(O)CC(O)C1CCCCCCC(O)=O DZUXGQBLFALXCR-UHFFFAOYSA-N 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 210000004623 platelet-rich plasma Anatomy 0.000 claims description 5
- 238000011321 prophylaxis Methods 0.000 claims description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 4
- 239000004593 Epoxy Substances 0.000 claims description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 4
- 238000004220 aggregation Methods 0.000 claims description 4
- 230000002776 aggregation Effects 0.000 claims description 4
- 230000004071 biological effect Effects 0.000 claims description 4
- 229910052681 coesite Inorganic materials 0.000 claims description 4
- 210000004351 coronary vessel Anatomy 0.000 claims description 4
- 229910052906 cristobalite Inorganic materials 0.000 claims description 4
- 239000013078 crystal Substances 0.000 claims description 4
- 230000002496 gastric effect Effects 0.000 claims description 4
- 230000003902 lesion Effects 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- DZUXGQBLFALXCR-CDIPTNKSSA-N prostaglandin F1alpha Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1CCCCCCC(O)=O DZUXGQBLFALXCR-CDIPTNKSSA-N 0.000 claims description 4
- 239000000377 silicon dioxide Substances 0.000 claims description 4
- 235000012239 silicon dioxide Nutrition 0.000 claims description 4
- 229910052682 stishovite Inorganic materials 0.000 claims description 4
- 229910052905 tridymite Inorganic materials 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 238000007605 air drying Methods 0.000 claims description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 3
- 210000001367 artery Anatomy 0.000 claims description 3
- 239000011248 coating agent Substances 0.000 claims description 3
- 238000000576 coating method Methods 0.000 claims description 3
- 210000003975 mesenteric artery Anatomy 0.000 claims description 3
- 239000011368 organic material Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- YIBNHAJFJUQSRA-YNNPMVKQSA-N prostaglandin H2 Chemical compound C1[C@@H]2OO[C@H]1[C@H](/C=C/[C@@H](O)CCCCC)[C@H]2C\C=C/CCCC(O)=O YIBNHAJFJUQSRA-YNNPMVKQSA-N 0.000 claims description 3
- 210000002784 stomach Anatomy 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 230000024883 vasodilation Effects 0.000 claims description 3
- 239000003071 vasodilator agent Substances 0.000 claims description 3
- 230000029663 wound healing Effects 0.000 claims description 3
- 238000004566 IR spectroscopy Methods 0.000 claims description 2
- UAGJVSRUFNSIHR-UHFFFAOYSA-N Methyl levulinate Chemical compound COC(=O)CCC(C)=O UAGJVSRUFNSIHR-UHFFFAOYSA-N 0.000 claims description 2
- 241000786363 Rhampholeon spectrum Species 0.000 claims description 2
- 208000007536 Thrombosis Diseases 0.000 claims description 2
- 239000012298 atmosphere Substances 0.000 claims description 2
- 230000037396 body weight Effects 0.000 claims description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 239000001569 carbon dioxide Substances 0.000 claims description 2
- 229960004424 carbon dioxide Drugs 0.000 claims description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 claims description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 235000019439 ethyl acetate Nutrition 0.000 claims description 2
- 150000002431 hydrogen Chemical group 0.000 claims description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 2
- 229910000043 hydrogen iodide Inorganic materials 0.000 claims description 2
- 239000012535 impurity Substances 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 claims description 2
- 238000001179 sorption measurement Methods 0.000 claims description 2
- 239000010409 thin film Substances 0.000 claims description 2
- 229940124549 vasodilator Drugs 0.000 claims description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 2
- 229920002554 vinyl polymer Polymers 0.000 claims description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 2
- KWKZCGMJGHHOKJ-ZKWNWVNESA-N Methyl Arachidonyl Fluorophosphonate Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCCP(F)(=O)OC KWKZCGMJGHHOKJ-ZKWNWVNESA-N 0.000 claims 1
- 150000004703 alkoxides Chemical class 0.000 claims 1
- 150000001450 anions Chemical class 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940102223 injectable solution Drugs 0.000 claims 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical group II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 25
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 241000700159 Rattus Species 0.000 description 8
- 230000003389 potentiating effect Effects 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 7
- 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 description 6
- 101000988802 Homo sapiens Hematopoietic prostaglandin D synthase Proteins 0.000 description 6
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 6
- 229960002986 dinoprostone Drugs 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 description 6
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 6
- BHMBVRSPMRCCGG-UHFFFAOYSA-N prostaglandine D2 Natural products CCCCCC(O)C=CC1C(CC=CCCCC(O)=O)C(O)CC1=O BHMBVRSPMRCCGG-UHFFFAOYSA-N 0.000 description 6
- 101100084403 Homo sapiens PRODH gene Proteins 0.000 description 5
- 101150059359 POX2 gene Proteins 0.000 description 5
- 102100028772 Proline dehydrogenase 1, mitochondrial Human genes 0.000 description 5
- 101100029251 Zea mays PER2 gene Proteins 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 230000003228 microsomal effect Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 210000003989 endothelium vascular Anatomy 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- DKNPRRRKHAEUMW-UHFFFAOYSA-N Iodine aqueous Chemical compound [K+].I[I-]I DKNPRRRKHAEUMW-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 108030003866 Prostaglandin-D synthases Proteins 0.000 description 2
- 102000048176 Prostaglandin-D synthases Human genes 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 230000005587 bubbling Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 229940020414 potassium triiodide Drugs 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- FMNQRUKVXAQEAZ-JNRFBPFXSA-N (5z,8s,9r,10e,12s)-9,12-dihydroxy-8-[(1s)-1-hydroxy-3-oxopropyl]heptadeca-5,10-dienoic acid Chemical compound CCCCC[C@H](O)\C=C\[C@@H](O)[C@H]([C@@H](O)CC=O)C\C=C/CCCC(O)=O FMNQRUKVXAQEAZ-JNRFBPFXSA-N 0.000 description 1
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 1
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 description 1
- RGQICUMNQVAHES-ARSRFYASSA-N 15S-hydroperoxy-PGE2 Chemical compound CCCCC[C@H](OO)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O RGQICUMNQVAHES-ARSRFYASSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 1
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010061459 Gastrointestinal ulcer Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 101000928408 Homo sapiens Protein diaphanous homolog 2 Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108090000769 Isomerases Proteins 0.000 description 1
- 102000004195 Isomerases Human genes 0.000 description 1
- 235000010624 Medicago sativa Nutrition 0.000 description 1
- 240000004658 Medicago sativa Species 0.000 description 1
- PJDMFGSFLLCCAO-NVRZHKMMSA-N PGF2alpha methyl ester Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(=O)OC PJDMFGSFLLCCAO-NVRZHKMMSA-N 0.000 description 1
- 229910019188 POF2 Inorganic materials 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 206010050902 Postoperative thrombosis Diseases 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 102100036469 Protein diaphanous homolog 2 Human genes 0.000 description 1
- 239000004133 Sodium thiosulphate Substances 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 229960000711 alprostadil Drugs 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940006138 antiglaucoma drug and miotics prostaglandin analogues Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 239000003633 blood substitute Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 239000003518 caustics Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000037020 contractile activity Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 230000002140 halogenating effect Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000328 pro-aggregatory effect Effects 0.000 description 1
- 150000003815 prostacyclins Chemical class 0.000 description 1
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000001625 seminal vesicle Anatomy 0.000 description 1
- 238000000822 sequential centrifugation Methods 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 125000004665 trialkylsilyl group Chemical group 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000002541 vasodepressive effect Effects 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 201000010653 vesiculitis Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
- C07D307/935—Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
- C07D307/935—Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans
- C07D307/937—Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans with hydrocarbon or substituted hydrocarbon radicals directly attached in position 2, e.g. prostacyclins
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Furan Compounds (AREA)
Priority Applications (19)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB19384/76A GB1583961A (en) | 1976-05-11 | 1976-05-11 | Prostacyclin and derivatives thereof |
| GB1938676A GB1583962A (en) | 1976-05-11 | 1976-05-11 | Prostacyclin derivatives |
| FR7710593A FR2351111A1 (fr) | 1976-05-11 | 1977-04-07 | Methylacetals de 2-(2b-ethynyl-cyclopent-1a-yl) acetaldehydes et leur preparation |
| ZA00772795A ZA772795B (en) | 1976-05-11 | 1977-05-10 | Ethers |
| NZ184057A NZ184057A (en) | 1976-05-11 | 1977-05-10 | Prostaglandin derivatives and pharmaceutica composition |
| NLAANVRAGE7705141,A NL181973C (nl) | 1976-05-11 | 1977-05-10 | Werkwijze voor het bereiden van farmaceutische preparaten op basis van prostaglandinederivaten en werkwijze voor het bereiden van prostaglandinederivaten. |
| JP5361977A JPS52136161A (en) | 1976-05-11 | 1977-05-10 | Novel prostaglandin derivative* its preparation and its use |
| BE177444A BE854463A (fr) | 1976-05-11 | 1977-05-10 | Ethers de prostaglandines |
| IL52053A IL52053A (en) | 1976-05-11 | 1977-05-10 | Prostacyclin and its biological preparation |
| AU25049/77A AU515715B2 (en) | 1976-05-11 | 1977-05-10 | Prostacyclin |
| DK205377A DK149953C (da) | 1976-05-11 | 1977-05-10 | Analogifremgangsmaade til fremstilling af prostaglandin-derivater |
| US06/795,524 US4539333A (en) | 1976-05-11 | 1977-05-10 | Prostacyclin, methods of using and method of making |
| SE7705423A SE436647B (sv) | 1976-05-11 | 1977-05-10 | Forfarande for framstellning av prostaglandinderivat (prostacyclin) |
| CA278,111A CA1097239A (en) | 1976-05-11 | 1977-05-10 | Enzymatic preparation of prostacyclin and its salts |
| IE950/77A IE46036B1 (en) | 1976-05-11 | 1977-05-10 | Prostacyclin and derivatives thereof |
| CH583777A CH637948A5 (en) | 1976-05-11 | 1977-05-10 | Process for the preparation of prostaglandin derivatives |
| ES458639A ES458639A1 (es) | 1976-05-11 | 1977-05-10 | Un procedimiento para preparar derivados de prostaglandina. |
| DE2720999A DE2720999C2 (de) | 1976-05-11 | 1977-05-10 | Postacyclin (bzw. (5Z)-5,6-Didehydro-9-desoxy-6,9α-epoxyprostaglandin F↓1↓↓α↓), Verfahren zu dessen Herstellung und diese Verbindung enthaltende pharmazeutische Formulierungen |
| AU68231/81A AU6823181A (en) | 1976-05-11 | 1981-03-10 | Prostacyclin salts |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB19384/76A GB1583961A (en) | 1976-05-11 | 1976-05-11 | Prostacyclin and derivatives thereof |
| GB3415176 | 1976-08-17 | ||
| GB3654776 | 1976-09-03 | ||
| GB4344576 | 1976-10-20 | ||
| GB5306076 | 1976-12-20 | ||
| GB1338977 | 1977-03-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB1583961A true GB1583961A (en) | 1981-02-04 |
Family
ID=27546654
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB19384/76A Expired GB1583961A (en) | 1976-05-11 | 1976-05-11 | Prostacyclin and derivatives thereof |
Country Status (12)
| Country | Link |
|---|---|
| JP (1) | JPS52136161A (enExample) |
| BE (1) | BE854463A (enExample) |
| CH (1) | CH637948A5 (enExample) |
| DE (1) | DE2720999C2 (enExample) |
| DK (1) | DK149953C (enExample) |
| FR (1) | FR2351111A1 (enExample) |
| GB (1) | GB1583961A (enExample) |
| IE (1) | IE46036B1 (enExample) |
| IL (1) | IL52053A (enExample) |
| NL (1) | NL181973C (enExample) |
| NZ (1) | NZ184057A (enExample) |
| SE (1) | SE436647B (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9492422B2 (en) | 2009-11-13 | 2016-11-15 | Toray Industries, Inc. | Therapeutic or prophylactic agent for diabetes |
| WO2017162668A1 (en) | 2016-03-23 | 2017-09-28 | CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. | Process for the preparation of epoprostenol sodium of enhanced stability |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI71138C (fi) * | 1976-12-31 | 1986-11-24 | Erba Farmitalia | Foerfarande foer framstaellning av terapeutiskt aktiva bisykliska prostaglandiner |
| US4178367A (en) | 1977-02-21 | 1979-12-11 | Ono Pharmaceutical Co. Ltd. | Prostaglandin I2 analogues |
| HU182583B (en) * | 1977-03-01 | 1984-02-28 | Chinoin Gyogyszer Es Vegyeszet | Process for preparing prostacyclin and analogues thereof |
| DE2743283A1 (de) * | 1977-09-27 | 1979-04-05 | Hoechst Ag | Neue prostacyclin-analoga |
| IT1088036B (it) | 1977-11-25 | 1985-06-04 | Erba Carlo Spa | 15-epi-prostaciclina e prostaciclina analoghi |
| DE2811950A1 (de) * | 1978-03-18 | 1979-12-13 | Hoechst Ag | Neue analoga von prostacyclin |
| ZA787353B (en) * | 1978-05-17 | 1980-08-27 | Wellcome Found | Pharmaceutical formulations |
| US4430340A (en) * | 1978-07-17 | 1984-02-07 | The Upjohn Company | Stabilization of PGI2 compounds with surfactants |
| IL58384A0 (en) | 1978-10-14 | 1980-01-31 | Beecham Group Ltd | 12-aza analogues of prostcyclin their preparation and pharmaceutical composition containing them |
| ZA815504B (en) * | 1980-09-15 | 1982-08-25 | Upjohn Co | Crystalline pgi2 methyl ester |
| CH651033A5 (de) * | 1981-03-11 | 1985-08-30 | Hoffmann La Roche | Fluorprostacycline. |
| DE3438870A1 (de) * | 1983-12-13 | 1985-06-13 | Stellmacher, Gerhard, Ing.(grad.), 8501 Schwaig | Spannvorrichtung fuer holzbearbeitungsmaschinen |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL51189A (en) * | 1976-02-04 | 1985-08-30 | Upjohn Co | Prostaglandin analogs |
-
1976
- 1976-05-11 GB GB19384/76A patent/GB1583961A/en not_active Expired
-
1977
- 1977-04-07 FR FR7710593A patent/FR2351111A1/fr not_active Withdrawn
- 1977-05-10 IE IE950/77A patent/IE46036B1/en not_active IP Right Cessation
- 1977-05-10 BE BE177444A patent/BE854463A/xx not_active IP Right Cessation
- 1977-05-10 DK DK205377A patent/DK149953C/da not_active IP Right Cessation
- 1977-05-10 SE SE7705423A patent/SE436647B/xx not_active IP Right Cessation
- 1977-05-10 IL IL52053A patent/IL52053A/xx unknown
- 1977-05-10 NZ NZ184057A patent/NZ184057A/xx unknown
- 1977-05-10 DE DE2720999A patent/DE2720999C2/de not_active Expired
- 1977-05-10 NL NLAANVRAGE7705141,A patent/NL181973C/xx not_active IP Right Cessation
- 1977-05-10 JP JP5361977A patent/JPS52136161A/ja active Granted
- 1977-05-10 CH CH583777A patent/CH637948A5/de not_active IP Right Cessation
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9492422B2 (en) | 2009-11-13 | 2016-11-15 | Toray Industries, Inc. | Therapeutic or prophylactic agent for diabetes |
| WO2017162668A1 (en) | 2016-03-23 | 2017-09-28 | CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. | Process for the preparation of epoprostenol sodium of enhanced stability |
Also Published As
| Publication number | Publication date |
|---|---|
| IE46036L (en) | 1977-11-11 |
| JPS52136161A (en) | 1977-11-14 |
| IE46036B1 (en) | 1983-02-09 |
| NL181973B (nl) | 1987-07-16 |
| SE7705423L (sv) | 1977-11-12 |
| IL52053A (en) | 1983-09-30 |
| DE2720999A1 (de) | 1977-11-24 |
| SE436647B (sv) | 1985-01-14 |
| NZ184057A (en) | 1979-10-25 |
| DK149953C (da) | 1987-06-29 |
| JPS619953B2 (enExample) | 1986-03-27 |
| NL181973C (nl) | 1987-12-16 |
| IL52053A0 (en) | 1977-07-31 |
| FR2351111A1 (fr) | 1977-12-09 |
| NL7705141A (nl) | 1977-11-15 |
| CH637948A5 (en) | 1983-08-31 |
| BE854463A (fr) | 1977-11-10 |
| DE2720999C2 (de) | 1986-09-18 |
| DK149953B (da) | 1986-11-03 |
| DK205377A (da) | 1977-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB1583961A (en) | Prostacyclin and derivatives thereof | |
| RU2127723C1 (ru) | Нитроэфиры, обладающие фармакологической активностью, и способы их получения | |
| US5004752A (en) | Novel 9-haloprostaglandins, processes for their preparation, and their use as medicinal agents | |
| SK3382000A3 (en) | A compound having structure of aromatic substituted prostaglandins and its use for the treatment of bone disorders | |
| IE47497B1 (en) | New prostacyclin derivatives,their manufacture and use | |
| US5625083A (en) | Dinitroglycerol esters of unsaturated fatty acids and prostaglandins | |
| US3928588A (en) | Method of reducing the undesirable gastrointestinal effects of prostaglandin synthetase inhibitors | |
| GB1595056A (en) | Pharmaceutical combination | |
| US4539333A (en) | Prostacyclin, methods of using and method of making | |
| US4883810A (en) | Ethers | |
| US4128713A (en) | 6,7-Didehydro-PGI1 compounds | |
| PL112539B1 (en) | Process for preparing novel derivatives of 11-desoxy-16-aryl-omega-tetranorprostaglandine | |
| US3755426A (en) | 10-haloprostaglandin-a derivatives | |
| FR2707089A1 (fr) | Nouveaux dérivés d'acide phosphonique, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. | |
| US3759978A (en) | 5,6-trans pge{11 | |
| EP0121350A2 (en) | Substituted unsaturated mercaptocarboxylic acids and derivatives as leukotriene antagonists | |
| US4285966A (en) | Certain 15-epi-prostacyclins | |
| JPS6112909B2 (enExample) | ||
| CA1218649A (en) | .delta..sup.8,.sup.9-prostaglandin derivatives, process for their manufacture and their use as medicaments | |
| SU1274621A3 (ru) | Способ получени производных простагландина | |
| US4048204A (en) | C20 and C22 acids to promote wound healing | |
| US4055574A (en) | 6,11-Dihydrodibenzo-[b.e.]-thiepin-11-one-3-thioacetates | |
| US2853497A (en) | 6, 8-bis (hydrocarbon substituted mercapto) 5-hydroxycaprylic acids and delta-lactones thereof | |
| US4425358A (en) | 13-Thia-prostacycline derivatives | |
| GB1583962A (en) | Prostacyclin derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PS | Patent sealed [section 19, patents act 1949] | ||
| 48S | Specification amended (sect. 8/1949) | ||
| SP | Amendment (slips) printed | ||
| 704A | Declaration that licence is not available as of right for an excepted use (par. 4a/1977) | ||
| PE20 | Patent expired after termination of 20 years |
Effective date: 19970509 |